SG11201900545TA - Pharmaceutical compounds - Google Patents
Pharmaceutical compoundsInfo
- Publication number
- SG11201900545TA SG11201900545TA SG11201900545TA SG11201900545TA SG11201900545TA SG 11201900545T A SG11201900545T A SG 11201900545TA SG 11201900545T A SG11201900545T A SG 11201900545TA SG 11201900545T A SG11201900545T A SG 11201900545TA SG 11201900545T A SG11201900545T A SG 11201900545TA
- Authority
- SG
- Singapore
- Prior art keywords
- almac
- house
- seagoe
- craigavon
- discovery
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 102220240796 rs553605556 Human genes 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 108010093668 Deubiquitinating Enzymes Proteins 0.000 abstract 1
- 102000001477 Deubiquitinating Enzymes Human genes 0.000 abstract 1
- 101000644843 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 19 Proteins 0.000 abstract 1
- 241000566145 Otus Species 0.000 abstract 1
- 102100020728 Ubiquitin carboxyl-terminal hydrolase 19 Human genes 0.000 abstract 1
- 102000018390 Ubiquitin-Specific Proteases Human genes 0.000 abstract 1
- 108010066496 Ubiquitin-Specific Proteases Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000012056 up-stream process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1612938.9A GB201612938D0 (en) | 2016-07-26 | 2016-07-26 | Pharmaceutical compounds |
| PCT/GB2017/052178 WO2018020242A1 (en) | 2016-07-26 | 2017-07-26 | Pharmaceutical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900545TA true SG11201900545TA (en) | 2019-02-27 |
Family
ID=56894331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900545TA SG11201900545TA (en) | 2016-07-26 | 2017-07-26 | Pharmaceutical compounds |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11053213B2 (enExample) |
| EP (1) | EP3490982B1 (enExample) |
| JP (1) | JP6986065B2 (enExample) |
| KR (1) | KR20190034564A (enExample) |
| CN (1) | CN109790146B (enExample) |
| AU (1) | AU2017304761C1 (enExample) |
| BR (1) | BR112019001253A2 (enExample) |
| CA (1) | CA3031036A1 (enExample) |
| ES (1) | ES2914677T3 (enExample) |
| GB (1) | GB201612938D0 (enExample) |
| IL (1) | IL264415B (enExample) |
| MX (1) | MX382624B (enExample) |
| SG (1) | SG11201900545TA (enExample) |
| WO (1) | WO2018020242A1 (enExample) |
| ZA (1) | ZA201900540B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201612938D0 (en) * | 2016-07-26 | 2016-09-07 | Almac Discovery Ltd | Pharmaceutical compounds |
| GB201617758D0 (en) * | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| US11465983B2 (en) | 2017-09-26 | 2022-10-11 | Dana-Farber Cancer Institute, Inc. | USP7 inhibitors for treating multiple myeloma |
| GB201801562D0 (en) * | 2018-01-31 | 2018-03-14 | Almac Diagnostics Ltd | Pharmaceutical compounds |
| UY38291A (es) * | 2018-07-05 | 2020-06-30 | Servier Lab | Nuevos derivados de amino-pirimidonilo un proceso para su preparación y composiciones farmacéuticas |
| JP7508449B2 (ja) | 2018-10-22 | 2024-07-01 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｕｓｐ７の阻害 |
| CN113365696A (zh) * | 2018-12-06 | 2021-09-07 | 阿尔麦克探索有限公司 | 药物化合物和其作为泛素特异性蛋白酶19(usp19)抑制剂的用途 |
| BR112021010645A2 (pt) * | 2018-12-06 | 2021-08-17 | Almac Discovery Limited | composto, 1-(((s)-7-((r)-3-ciclohexil-2-metilpropanoil)-10-hidroxi-7-azaspiro[4.5]decan-10-il)metil)-4-fenil-5-(piperazina-1-carbonila)piridin-2(1h)-ona, composição farmacêutica, métodos para tratamento de obesidade, de resistência à insulina, de diabetes tipo ii, de atrofia muscular, de câncer e para reduzir perda de massa muscular, e, inibidor de usp19 |
| WO2020227365A1 (en) | 2019-05-06 | 2020-11-12 | Integral Early Discovery, Inc. | Inhibiting usp19 |
| MX2022005819A (es) * | 2019-11-13 | 2022-08-16 | Univ Temple | Nuevas lactonas funcionalizadas como moduladores del receptor 7 de 5-hidroxitriptamina y su método de uso. |
| CN111039860B (zh) * | 2019-12-02 | 2022-09-13 | 河北科技大学 | 2-羟基-n-(4’-氯联苯-2-基)烟酰胺的合成方法及应用 |
| GB202001980D0 (en) * | 2020-02-13 | 2020-04-01 | Almac Discovery Ltd | Therapeutic mentods |
| USD991067S1 (en) | 2020-10-17 | 2023-07-04 | Honeywell International Inc. | Modular aspirated smoke, gas, and air quality monitoring system device |
| GB202104097D0 (en) | 2021-03-24 | 2021-05-05 | Almac Discovery Ltd | Pharmaceutical compounds |
| JP2025513455A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| GB202311227D0 (en) | 2023-07-21 | 2023-09-06 | Almac Discovery Ltd | Pharmaceutical compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPO111096A0 (en) * | 1996-07-18 | 1996-08-08 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| JP2003501428A (ja) | 1999-06-02 | 2003-01-14 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ピロリジニル、ピペリジニルもしくはホモピペリジニル置換（ベンゾジオキサン、ベンゾフランもしくはベンゾピラン）誘導体 |
| EP2552013A1 (en) * | 2011-07-27 | 2013-01-30 | Siemens Aktiengesellschaft | Reduction of noise and vibrations of an electromechanical transducer by using a modified stator coil drive signal comprising harmonic components |
| GB201114448D0 (en) * | 2011-08-22 | 2011-10-05 | Takeda Pharmaceutical | Compounds and their use |
| EP2565186A1 (en) * | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| JP6535007B2 (ja) | 2013-12-20 | 2019-06-26 | インスティテュート オブ ファーマコロジー アンド トキシコロジー アカデミー オブ ミリタリー メディカル サイエンシズ ピー．エル．エー．チャイナ | 新規ピペリジンカルボキサミド化合物、その調製方法及び使用 |
| TWI698436B (zh) * | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶 |
| GB201612938D0 (en) * | 2016-07-26 | 2016-09-07 | Almac Discovery Ltd | Pharmaceutical compounds |
| GB201617758D0 (en) * | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
-
2016
- 2016-07-26 GB GBGB1612938.9A patent/GB201612938D0/en not_active Ceased
-
2017
- 2017-07-26 WO PCT/GB2017/052178 patent/WO2018020242A1/en not_active Ceased
- 2017-07-26 US US16/319,961 patent/US11053213B2/en active Active
- 2017-07-26 ES ES17748875T patent/ES2914677T3/es active Active
- 2017-07-26 BR BR112019001253A patent/BR112019001253A2/pt not_active IP Right Cessation
- 2017-07-26 MX MX2019001011A patent/MX382624B/es unknown
- 2017-07-26 SG SG11201900545TA patent/SG11201900545TA/en unknown
- 2017-07-26 KR KR1020197004797A patent/KR20190034564A/ko not_active Ceased
- 2017-07-26 CA CA3031036A patent/CA3031036A1/en active Pending
- 2017-07-26 EP EP17748875.6A patent/EP3490982B1/en active Active
- 2017-07-26 CN CN201780057475.6A patent/CN109790146B/zh not_active Expired - Fee Related
- 2017-07-26 AU AU2017304761A patent/AU2017304761C1/en not_active Ceased
- 2017-07-26 JP JP2019503928A patent/JP6986065B2/ja active Active
-
2019
- 2019-01-22 IL IL264415A patent/IL264415B/en unknown
- 2019-01-25 ZA ZA2019/00540A patent/ZA201900540B/en unknown
-
2021
- 2021-07-06 US US17/368,290 patent/US12466805B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201900540B (en) | 2022-07-27 |
| CA3031036A1 (en) | 2018-02-01 |
| RU2019105179A (ru) | 2020-08-27 |
| JP6986065B2 (ja) | 2021-12-22 |
| US20220002264A1 (en) | 2022-01-06 |
| US11053213B2 (en) | 2021-07-06 |
| JP2019523266A (ja) | 2019-08-22 |
| WO2018020242A1 (en) | 2018-02-01 |
| IL264415A (en) | 2019-02-28 |
| CN109790146B (zh) | 2022-08-23 |
| US12466805B2 (en) | 2025-11-11 |
| RU2019105179A3 (enExample) | 2020-10-19 |
| CN109790146A (zh) | 2019-05-21 |
| BR112019001253A2 (pt) | 2019-05-07 |
| ES2914677T3 (es) | 2022-06-15 |
| MX382624B (es) | 2025-03-13 |
| MX2019001011A (es) | 2019-05-23 |
| KR20190034564A (ko) | 2019-04-02 |
| AU2017304761B2 (en) | 2021-06-03 |
| EP3490982A1 (en) | 2019-06-05 |
| US20190233394A1 (en) | 2019-08-01 |
| IL264415B (en) | 2022-02-01 |
| GB201612938D0 (en) | 2016-09-07 |
| EP3490982B1 (en) | 2022-04-20 |
| AU2017304761A1 (en) | 2019-01-31 |
| AU2017304761C1 (en) | 2021-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201809559UA (en) | Substituted pyridines as inhibitors of dnmt1 | |
| SG11201903456WA (en) | Piperidine derivatives as inhibitors of ubiquitin specific protease 7 | |
| SG11201908114UA (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| SG11201806700RA (en) | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof | |
| SG11201809064QA (en) | Chimeric neurotoxins | |
| SG11201811414TA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201808682XA (en) | Silicone atoms containing ivacaftor analogues | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201810366WA (en) | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | |
| SG11201407546QA (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| SG11201407458XA (en) | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | |
| SG11201809625RA (en) | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201901374WA (en) | Antibiotic compounds | |
| SG11201910197SA (en) | Compounds for treating dengue virus infection and other viral infections | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same |